AU2010259284A1 - Use of a composition for the treatment of mucositis - Google Patents

Use of a composition for the treatment of mucositis Download PDF

Info

Publication number
AU2010259284A1
AU2010259284A1 AU2010259284A AU2010259284A AU2010259284A1 AU 2010259284 A1 AU2010259284 A1 AU 2010259284A1 AU 2010259284 A AU2010259284 A AU 2010259284A AU 2010259284 A AU2010259284 A AU 2010259284A AU 2010259284 A1 AU2010259284 A1 AU 2010259284A1
Authority
AU
Australia
Prior art keywords
composition
mucositis
chitosan
range
negatively charged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010259284A
Other languages
English (en)
Inventor
Lars Adolfsson
Olle Larm
Anders Westermark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EXTHERA AB
Original Assignee
EXTHERA AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EXTHERA AB filed Critical EXTHERA AB
Publication of AU2010259284A1 publication Critical patent/AU2010259284A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2010259284A 2009-06-10 2010-06-10 Use of a composition for the treatment of mucositis Abandoned AU2010259284A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0950441 2009-06-10
SE0950441-6 2009-06-10
PCT/SE2010/050650 WO2010144044A1 (en) 2009-06-10 2010-06-10 Use of a composition for the treatment of mucositis

Publications (1)

Publication Number Publication Date
AU2010259284A1 true AU2010259284A1 (en) 2011-12-15

Family

ID=43309105

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010259284A Abandoned AU2010259284A1 (en) 2009-06-10 2010-06-10 Use of a composition for the treatment of mucositis

Country Status (9)

Country Link
US (1) US8906883B2 (cg-RX-API-DMAC10.html)
EP (1) EP2440216A4 (cg-RX-API-DMAC10.html)
JP (1) JP2012529506A (cg-RX-API-DMAC10.html)
CN (1) CN102458419A (cg-RX-API-DMAC10.html)
AU (1) AU2010259284A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI1009741A2 (cg-RX-API-DMAC10.html)
CA (1) CA2763092A1 (cg-RX-API-DMAC10.html)
RU (1) RU2011152518A (cg-RX-API-DMAC10.html)
WO (1) WO2010144044A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2773017T3 (es) 2010-04-06 2020-07-09 Synedgen Inc Derivados de quitosano para el tratamiento de mucositis o ulceración
US10022393B2 (en) 2012-09-20 2018-07-17 Synedgen, Inc. Methods for treatment or prevention of damage resulting from radiation, trauma or shock
WO2015022907A1 (ja) * 2013-08-13 2015-02-19 生化学工業株式会社 カチオン化キトサンを含有する医薬
US20160287626A1 (en) * 2013-10-22 2016-10-06 Cantex Pharmaceuticals, Inc. Methods of treating and preventing radiation damage
US20180228832A1 (en) * 2015-08-18 2018-08-16 Pharma Seeds Create, Llc Stomatological composition containing nsaid or heparin compound
WO2019211483A1 (en) * 2018-05-04 2019-11-07 Bonoss Medical Aktiebolag A composition for reduction of scar formation
CA3102284A1 (en) 2018-06-03 2019-12-12 Glycomira Therapeutics, Inc. Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and/or chemotherapy
WO2021216494A1 (en) * 2020-04-24 2021-10-28 Intact Therapeutics, Inc. Compositions and methods for treatment of gastrointestinal bleeding
EP3981505B1 (en) * 2020-10-12 2024-11-27 Gambro Lundia AB Membrane with immobilized anticoagulant and process for producing same
SE545090C2 (en) * 2021-03-17 2023-03-28 Labrida As A hydrogel comprising chitosan for use in prevention and treatment of periodontal and peri-implant disease
WO2023044132A2 (en) * 2021-09-17 2023-03-23 Shawn Walker Use of chitosan complexes or compositions to reduce infiltration of environmental factors into the brain

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402531L (sv) * 1994-07-19 1996-01-20 Medicarb Ab Sårläkningsmedel
SE9402529D0 (sv) * 1994-07-19 1994-07-19 Astra Ab Anti-adherensmedel
SE507028C2 (sv) * 1996-08-06 1998-03-16 Medicarb Ab Ny medicinsk användning
DK1997478T3 (da) * 2001-02-15 2013-12-09 Access Pharma Inc Flydende formuleringer til forebyggelse og behandling af slimhindesygdomme og -lidelser
AU2002249046A1 (en) * 2001-04-23 2002-11-05 Nucryst Pharmaceuticals Corp. Lubricious coatings for substrates
EP1539192A1 (en) * 2002-04-24 2005-06-15 Medicarb AB Composition and kit for the treatment of inflammatory bowel diseases
WO2004032843A2 (en) * 2002-10-07 2004-04-22 Orapharma, Inc. Mucoadhesive tetracycline formulations
US20060058390A1 (en) * 2004-09-14 2006-03-16 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
EP1838335A1 (en) 2005-01-19 2007-10-03 Bonoss Medical AB Growth factor composition
DE102006024831B4 (de) 2006-05-24 2008-03-27 Heraeus Quarzglas Gmbh & Co. Kg Verfahren zur Herstellung eines Halbzeugs aus synthetischem Quarzglas
WO2008060764A2 (en) 2006-10-05 2008-05-22 Drugtech Corporation Topical therapies for oral mucositis and other conditions

Also Published As

Publication number Publication date
RU2011152518A (ru) 2013-07-20
EP2440216A4 (en) 2013-09-11
WO2010144044A1 (en) 2010-12-16
CA2763092A1 (en) 2010-12-16
US8906883B2 (en) 2014-12-09
EP2440216A1 (en) 2012-04-18
JP2012529506A (ja) 2012-11-22
CN102458419A (zh) 2012-05-16
US20120077773A1 (en) 2012-03-29
BRPI1009741A2 (pt) 2016-03-15

Similar Documents

Publication Publication Date Title
US8906883B2 (en) Treatment of oral mucositis by administering an ionic complex of chitosan and a negatively charged polysaccharide selected from heparin, heparan sulfate and dextran sulfate
JP4354528B2 (ja) 間質性膀胱炎の治療へのヒアルロン酸の使用
JP4194653B2 (ja) アフタ口内潰瘍に伴う痛みの即効的解放のための薬剤組成物
KR930003117B1 (ko) 황산화 이당류를 활성성분으로 함유하는 염증예방 또는 치료용 제약조성물
KR100761051B1 (ko) 점막염, 구내염 및 베체트 증후군 치료용 약학적 조성물
EP2525803B1 (en) Antimicrobial agentcomprising peroxide, alcohol and chelating agent
US20100144618A1 (en) Compositions containing an intestinal trefoil peptide and a mucoadhesive
JPH09512797A (ja) 癌の治療および転移の予防
WO2002085402A1 (en) Methods and compositions for treating oral and eosophageal lesions
AU694113B2 (en) Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
CA2152398A1 (en) Hyaluronic acid-urea pharmaceutical compositions and uses
EP0988040A1 (en) Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain
HU228669B1 (en) Pharmaceutical compositions for the treatment of painful, inflammatory and ulcerative conditions of moist epithelial surfaces such as mucositis, stomatitis and behcet's syndrome
JP4685242B2 (ja) ヒアルロン酸を用いた放射線膀胱炎の予防、軽減、および治療法
Koshariya et al. Role of topical Sucralfate in healing of burn wounds
JP2018538315A (ja) 骨関節炎治療のための親水化されたスルファサラジンおよびヒアルロン酸を含む組成物およびその製造方法
EP3087990A1 (en) Gel-forming agent containing sulfonamide and chitosan and having a powdered dosage form
RU2258516C1 (ru) Способ лечения красного плоского лишая
WO2015023226A1 (en) Use of a composition comprising chitosan and a negatively charge polysaccharide for the treament of salivary dysfuntion
EP3849514A1 (en) A composition for use in the prevention and/or treatment of epistaxis
WO2025129601A1 (en) Method for treating epidermolysis bullosa
EP3787593A1 (en) A composition for reduction of scar formation
TW202545544A (zh) 普維酮碘及生物聚合物的藥用組合物及製造其之方法
WO2006022536A1 (en) New medical use of the meldonium
JP2688733B2 (ja) 消化管粘膜障害の予防及び治療剤

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period